Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 228

1.

Inhibition of androgen receptor transcriptional activity as a novel mechanism of action of arsenic.

Rosenblatt AE, Burnstein KL.

Mol Endocrinol. 2009 Mar;23(3):412-21. doi: 10.1210/me.2008-0235. Epub 2009 Jan 8.

2.

Prolonged androgen receptor loading onto chromatin and the efficient recruitment of p160 coactivators contribute to androgen-independent growth of prostate cancer cells.

Shi XB, Xue L, Zou JX, Gandour-Edwards R, Chen H, deVere White RW.

Prostate. 2008 Dec 1;68(16):1816-26. doi: 10.1002/pros.20849.

PMID:
18780293
3.
4.

5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors.

Gravina GL, Marampon F, Di Staso M, Bonfili P, Vitturini A, Jannini EA, Pestell RG, Tombolini V, Festuccia C.

Prostate. 2010 Aug;70(11):1166-78. doi: 10.1002/pros.21151.

PMID:
20333699
5.

Prohibitin and the SWI/SNF ATPase subunit BRG1 are required for effective androgen antagonist-mediated transcriptional repression of androgen receptor-regulated genes.

Dai Y, Ngo D, Jacob J, Forman LW, Faller DV.

Carcinogenesis. 2008 Sep;29(9):1725-33. doi: 10.1093/carcin/bgn117. Epub 2008 May 16.

6.

Regulation of FGF8 expression by the androgen receptor in human prostate cancer.

Gnanapragasam VJ, Robson CN, Neal DE, Leung HY.

Oncogene. 2002 Aug 1;21(33):5069-80.

7.

A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes.

Cherian MT, Wilson EM, Shapiro DJ.

J Biol Chem. 2012 Jul 6;287(28):23368-80. doi: 10.1074/jbc.M112.344671. Epub 2012 May 15.

8.

A novel androgen receptor-binding element modulates Cdc6 transcription in prostate cancer cells during cell-cycle progression.

Jin F, Fondell JD.

Nucleic Acids Res. 2009 Aug;37(14):4826-38. doi: 10.1093/nar/gkp510. Epub 2009 Jun 11.

9.

Preclinical pharmacology of FL442, a novel nonsteroidal androgen receptor modulator.

Poutiainen PK, Huhtala T, Jääskeläinen T, Petsalo A, Küblbeck J, Kaikkonen S, Palvimo JJ, Raunio H, Närvänen A, Peräkylä M, Juvonen RO, Honkakoski P, Laatikainen R, Pulkkinen JT.

Mol Cell Endocrinol. 2014 Apr 25;387(1-2):8-18. doi: 10.1016/j.mce.2014.02.008. Epub 2014 Feb 22.

PMID:
24565895
10.

CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.

Ishikura N, Kawata H, Nishimoto A, Nakamura R, Tsunenari T, Watanabe M, Tachibana K, Shiraishi T, Yoshino H, Honma A, Emura T, Ohta M, Nakagawa T, Houjo T, Corey E, Vessella RL, Aoki Y, Sato H.

Int J Oncol. 2015 Apr;46(4):1560-72. doi: 10.3892/ijo.2015.2860. Epub 2015 Jan 30.

PMID:
25634071
11.

Telomerase as an important target of androgen signaling blockade for prostate cancer treatment.

Liu S, Qi Y, Ge Y, Duplessis T, Rowan BG, Ip C, Cheng H, Rennie PS, Horikawa I, Lustig AJ, Yu Q, Zhang H, Dong Y.

Mol Cancer Ther. 2010 Jul;9(7):2016-25. doi: 10.1158/1535-7163.MCT-09-0924. Epub 2010 Jun 22.

12.

Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.

Wang Y, Liu G, Tong D, Parmar H, Hasenmayer D, Yuan W, Zhang D, Jiang J.

Prostate. 2015 Aug 1;75(11):1187-96. doi: 10.1002/pros.23000. Epub 2015 Apr 20.

PMID:
25894097
13.

Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.

Kawata H, Arai S, Nakagawa T, Ishikura N, Nishimoto A, Yoshino H, Shiraishi T, Tachibana K, Nakamura R, Sato H.

Prostate. 2011 Sep;71(12):1344-56. doi: 10.1002/pros.21351. Epub 2011 Feb 9.

PMID:
21308717
14.

Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.

Pandini G, Mineo R, Frasca F, Roberts CT Jr, Marcelli M, Vigneri R, Belfiore A.

Cancer Res. 2005 Mar 1;65(5):1849-57.

15.

Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor.

Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP.

J Biol Chem. 2002 Jul 19;277(29):26321-6. Epub 2002 May 15.

17.

Effects of treatment with androgen receptor ligands on microRNA expression of prostate cancer cells.

Segal CV, Koufaris C, Powell C, Gooderham NJ.

Toxicology. 2015 Jul 3;333:45-52. doi: 10.1016/j.tox.2015.04.002. Epub 2015 Apr 3.

PMID:
25846647
18.

Androgen receptor functional analyses by high throughput imaging: determination of ligand, cell cycle, and mutation-specific effects.

Szafran AT, Szwarc M, Marcelli M, Mancini MA.

PLoS One. 2008;3(11):e3605. doi: 10.1371/journal.pone.0003605. Epub 2008 Nov 3.

19.

Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.

Gravina GL, Festuccia C, Millimaggi D, Dolo V, Tombolini V, de Vito M, Vicentini C, Bologna M.

Prostate. 2008 May 15;68(7):793-801. doi: 10.1002/pros.20748.

PMID:
18324645
20.

Supplemental Content

Support Center